Floatz logo

Romidepsin

Bone Marrow Failure

Memorial Sloan Kettering Cancer CenterSmall moleculePhase 2/3Active
B
63/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
48/ 100
Competitive Position
95/ 100

Competitive context

15 Active assets in the Bone Marrow Failure cohort.

Asset / SponsorPhaseRating
Fludarabine
Fred Hutchinson Cancer Center
Phase 2/3BBB
Cyclophosphamide
Memorial Sloan Kettering Cancer Center
Phase 2/3BBB
Busulphan
Memorial Sloan Kettering Cancer Center
Phase 2/3BB
IMMUNOGLOBULIN G1 (HUMAN-RAT MONOCLONAL CAMPATH-1H .GAMMA.1-CHAIN ANTI-HUMAN ANTIGEN CD52), DISULFIDE WITH HUMAN-RAT MONOCLONAL CAMPATH-1H LIGHT CHAIN, DIMER
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2/3BB
Evomela
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2B

View all 19 →

Same molecule, other indications

Romidepsin is also rated in:

Myelodysplastic/Myeloproliferative DiseasesDormant
BBB
Indicative ·
76 / 100
View asset →
Recurrent Mycosis Fungoides/Sezary SyndromeDormant
BBB
Indicative ·
75 / 100
View asset →
Multiple Myeloma and Plasma Cell NeoplasmDormant
BBB
Indicative ·
74 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →